Clinical Trials Logo

Urologic Diseases clinical trials

View clinical trials related to Urologic Diseases.

Filter by:

NCT ID: NCT03010813 Completed - Clinical trials for Colorectal Neoplasms

A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery

Start date: December 2016
Phase: N/A
Study type: Interventional

This is a prospective, single center, multispecialty study that aimed to evaluate the clinical feasibility and safety of single port surgery and NOTES (mainly transanal and transoral surgery) using a novel single port robotic system.

NCT ID: NCT02891460 Completed - Neoplasms Clinical Trials

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Start date: January 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the clinical response of the tumors within the bladder of recurrent NMIBC patients to Mitomycin-C embedded in UroGen Pharma's (known at that time as TheraCoat Ltd.) TC-3 Sterile Hydrogel (TC-3) and to evaluate the patency of ureters 6 hr post instillation.

NCT ID: NCT02811601 Completed - Urologic Diseases Clinical Trials

Percutaneous Externally-Assembled Laparoscopic Urologic Surgery

Start date: June 2016
Phase: N/A
Study type: Interventional

This will be a single-arm prospective internally-controlled study. Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.

NCT ID: NCT02805504 Completed - Clinical trials for Urinary Tract Diseases

Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures

Start date: July 11, 2016
Phase: Phase 4
Study type: Interventional

A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.

NCT ID: NCT02774031 Completed - Clinical trials for Female Urogenital Diseases

Comparison of Gas Consumption From Two Different Anesthesia Machines

Start date: May 2016
Phase: N/A
Study type: Interventional

Low flow anesthesia (LFA) is used less than desirable, partly because one has considered that there might be danger of underdosing of anesthesia gas and thus risk of awareness under anesthesia.LFA has several advantages such as reducing loss of moisture and heat in the inhaled air under anesthesia and to reduce the consumption of anesthetic gas. A few anesthesia machines include an automatic gas control system: the Aisys machine, by GE Healthcare (Madison, WI, USA), and the Flow-i machine, by Maquet (Sweden). Since these machines were introduced, only a few studies have reported their functionality and effect on gas consumption. 20 to 55% reduction of gas consumption was found. The potential reduction may have been underestimated because in the majority of cases a FGF higher than 1 l/min was still used. In this study the consumption of anesthetic gas (desflurane) delivered by two different anesthesia machines (Aisys and Flow-i) will be compared, with and without gas control delivery systems. Gas consumption and the time needed to reach the target level of anesthetic gas concentration will be assessed. Data needed will be collected directly from the anesthesia machine, PICIS ( Electronic anesthesia record) and EPJ (Electronic patient journal). The results of this study are of interest for intraoperative ventilation and of economic and ecological interest

NCT ID: NCT02622269 Completed - Urologic Diseases Clinical Trials

Patient-driven Compression in Urography

Start date: April 2015
Phase: N/A
Study type: Interventional

Compression of the abdomen during urography with either a patient-regulated compression device or conventional compression. Evaluation of radiation dose, image quality and patients' experiences

NCT ID: NCT02543645 Terminated - Clinical trials for Non-small Cell Lung Cancer

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Start date: October 2015
Phase: Phase 1
Study type: Interventional

This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).* *Note: This Study was terminated prior to initiation of Phase II

NCT ID: NCT02444013 Recruiting - Kidney Diseases Clinical Trials

Folic Acid for Prevention of Contrast Induced Nephropathy

FAPCIN
Start date: May 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether periprocedural administration of folic acid is effective in the prevention of contrast induced nephropathy in patients undergoing coronary CTA/angiography/angioplasty.

NCT ID: NCT02401542 Terminated - Clinical trials for Urinary Bladder Disease

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

FIERCE-21
Start date: June 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel, or versus docetaxel in FGFR3 mutant/fusion subjects with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are refractory to at least one prior line of chemotherapy. This study is divided into 3 phases: Phase 1b (Cohort 1), Phase 2 (Cohorts 2 and 3), and Phase 2b (Monotherapy Expansion Phase and Randomized Phase).

NCT ID: NCT02386111 Terminated - Neoplasms Clinical Trials

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Start date: May 2015
Phase: Phase 1
Study type: Interventional

This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and sunitinib. The study will enroll patients with metastatic clear cell renal cell carcinoma.